Freedland et al determined the risk of prostate cancer-specific survival after biochemical recurrence in men who have undergone radical prostatectomy. This can help identify patients who may benefit from more aggressive management. The authors are from the James Buchanan Brady Urological Institute and University of Southern California Los Angeles.
Criteria for biochemical recurrence: serum PSA >= 0.2 ng/mL
Parameters:
(1) number of years between radical prostatectomy and biochemical recurrence
(2) Gleason score of original prostate cancer
(3) PSA doubling time (PSADT)
|
Years |
Gleason Score |
PSADT in Months |
5 Year Survival |
|---|---|---|---|
|
<= 3 |
< 8 |
< 3.0 |
74% |
|
<= 3 |
< 8 |
3.0 to 8.9 |
91% |
|
<= 3 |
< 8 |
9.0 to 14.9 |
97% |
|
<= 3 |
< 8 |
>= 15 |
99% |
|
<= 3 |
>= 8 |
< 3.0 |
51% |
|
<= 3 |
>= 8 |
3.0 to 8.9 |
81% |
|
<= 3 |
>= 8 |
9.0 to 14.9 |
94% |
|
<= 3 |
>= 8 |
>= 15 |
98% |
|
> 3 |
< 8 |
< 3.0 |
92% |
|
> 3 |
< 8 |
3.0 to 8.9 |
97% |
|
> 3 |
< 8 |
9.0 to 14.9 |
99% |
|
> 3 |
< 8 |
>= 15 |
100% |
|
> 3 |
>= 8 |
< 3.0 |
83% |
|
> 3 |
>= 8 |
3.0 to 8.9 |
94% |
|
> 3 |
>= 8 |
9.0 to 14.9 |
98% |
|
> 3 |
>= 8 |
>= 15 |
99% |
where:
• The 95% confidence intervals are given in Table 3, page 437.
|
Years |
Gleason Score |
PSADT in Months |
10 Year Survival |
|---|---|---|---|
|
<= 3 |
< 8 |
< 3.0 |
15% |
|
<= 3 |
< 8 |
3.0 to 8.9 |
55% |
|
<= 3 |
< 8 |
9.0 to 14.9 |
85% |
|
<= 3 |
< 8 |
>= 15 |
93% |
|
<= 3 |
>= 8 |
< 3.0 |
1% |
|
<= 3 |
>= 8 |
3.0 to 8.9 |
26% |
|
<= 3 |
>= 8 |
9.0 to 14.9 |
69% |
|
<= 3 |
>= 8 |
>= 15 |
86% |
|
> 3 |
< 8 |
< 3.0 |
59% |
|
> 3 |
< 8 |
3.0 to 8.9 |
84% |
|
> 3 |
< 8 |
9.0 to 14.9 |
95% |
|
> 3 |
< 8 |
>= 15 |
98% |
|
> 3 |
>= 8 |
< 3.0 |
30% |
|
> 3 |
>= 8 |
3.0 to 8.9 |
68% |
|
> 3 |
>= 8 |
9.0 to 14.9 |
90% |
|
> 3 |
>= 8 |
>= 15 |
96% |
|
Years |
Gleason Score |
PSADT in Months |
15 Year Survival |
|---|---|---|---|
|
<= 3 |
< 8 |
< 3.0 |
< 1% |
|
<= 3 |
< 8 |
3.0 to 8.9 |
16% |
|
<= 3 |
< 8 |
9.0 to 14.9 |
59% |
|
<= 3 |
< 8 |
>= 15 |
81% |
|
<= 3 |
>= 8 |
< 3.0 |
< 1% |
|
<= 3 |
>= 8 |
3.0 to 8.9 |
1% |
|
<= 3 |
>= 8 |
9.0 to 14.9 |
31% |
|
<= 3 |
>= 8 |
>= 15 |
62% |
|
> 3 |
< 8 |
< 3.0 |
19% |
|
> 3 |
< 8 |
3.0 to 8.9 |
59% |
|
> 3 |
< 8 |
9.0 to 14.9 |
86% |
|
> 3 |
< 8 |
>= 15 |
94% |
|
> 3 |
>= 8 |
< 3.0 |
2% |
|
> 3 |
>= 8 |
3.0 to 8.9 |
30% |
|
> 3 |
>= 8 |
9.0 to 14.9 |
72% |
|
> 3 |
>= 8 |
>= 15 |
87% |
Purpose: To predict prostate-cancer specific mortality in men with biochemical recurrence after a radical prostatectomy based on the study of Freedland et al.
Specialty: Hematology Oncology, Surgery, general, Urology
Objective: severity, prognosis, stage
ICD-10: C61,
